Aeglea Bio Therapeutics Inc (AGLE) CEO Anthony G. Quinn Buys 8,989 Shares

Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Anthony G. Quinn purchased 8,989 shares of the company’s stock in a transaction that occurred on Monday, May 20th. The shares were bought at an average cost of $6.56 per share, with a total value of $58,967.84. Following the transaction, the chief executive officer now directly owns 304,135 shares of the company’s stock, valued at approximately $1,995,125.60. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

AGLE stock traded down $0.06 on Friday, hitting $6.71. 14,537 shares of the company were exchanged, compared to its average volume of 179,774. Aeglea Bio Therapeutics Inc has a twelve month low of $6.31 and a twelve month high of $12.00. The firm has a market capitalization of $193.57 million, a price-to-earnings ratio of -3.15 and a beta of 0.89.

Aeglea Bio Therapeutics (NASDAQ:AGLE) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.04). Sell-side analysts anticipate that Aeglea Bio Therapeutics Inc will post -2.19 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. increased its position in shares of Aeglea Bio Therapeutics by 25.1% in the third quarter. BlackRock Inc. now owns 1,028,996 shares of the biotechnology company’s stock worth $9,847,000 after acquiring an additional 206,491 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Aeglea Bio Therapeutics by 7.9% in the third quarter. Vanguard Group Inc. now owns 753,031 shares of the biotechnology company’s stock worth $7,207,000 after acquiring an additional 55,193 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Aeglea Bio Therapeutics by 81.1% in the third quarter. Dimensional Fund Advisors LP now owns 166,321 shares of the biotechnology company’s stock worth $1,592,000 after acquiring an additional 74,473 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Aeglea Bio Therapeutics in the fourth quarter worth $37,000. Finally, Vanguard Group Inc increased its position in shares of Aeglea Bio Therapeutics by 7.9% in the third quarter. Vanguard Group Inc now owns 753,031 shares of the biotechnology company’s stock worth $7,207,000 after acquiring an additional 55,193 shares in the last quarter. 58.59% of the stock is owned by institutional investors.

Several equities analysts recently commented on the stock. JPMorgan Chase & Co. assumed coverage on shares of Aeglea Bio Therapeutics in a research report on Thursday, March 21st. They set an “overweight” rating and a $14.00 price target for the company. ValuEngine lowered shares of Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 9th. Finally, HC Wainwright assumed coverage on shares of Aeglea Bio Therapeutics in a research report on Tuesday. They set a “buy” rating and a $20.00 price target for the company. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $16.00.

ILLEGAL ACTIVITY WARNING: “Aeglea Bio Therapeutics Inc (AGLE) CEO Anthony G. Quinn Buys 8,989 Shares” was originally reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this story on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark laws. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/24/aeglea-bio-therapeutics-inc-agle-ceo-anthony-g-quinn-buys-8989-shares.html.

Aeglea Bio Therapeutics Company Profile

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.

Further Reading: Forex

Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.